Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype? (Q38209866)

31 August 2017

title

Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype? (English)

1 reference

31 August 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24802998%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Franck Dumetz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24802998%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Alicia Ponte-sucre

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24802998%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Jorge Arevalo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24802998%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Syamal Roy

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24802998%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Jean-Claude Dujardin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24802998%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

6 May 2014

1 reference

Expert Review of Anti-infective Therapy

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24802998%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24802998%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24802998%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

937-946

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24802998%20AND%20SRC:MED&resulttype=core&format=json

Clinical pleiomorphism in human leishmaniases, with special mention of asymptomatic infection

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Use of antimony in the treatment of leishmaniasis: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Unresponsiveness to AmBisome in some Sudanese patients with kala-azar.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Drug regimens for visceral leishmaniasis in Mediterranean countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

(Post-) Genomic approaches to tackle drug resistance in Leishmania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Adaptive mechanisms in pathogens: universal aneuploidy in Leishmania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Drug-resistant microorganisms with a higher fitness--can medicines boost pathogens?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

The immune response to Leishmania: mechanisms of parasite control and evasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Interleukin-10 and the pathogenesis of human visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Regulatory T cells suppress T cell activation at the pathologic site of human visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Immunomodulatory effects of antileishmanial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Polymerase chain reaction detection of Leishmania kDNA from the urine of Peruvian patients with cutaneous and mucocutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Detection of Leishmania in unaffected mucosal tissues of patients with cutaneous leishmaniasis caused by Leishmania (Viannia) species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Leishmania DNA is rapidly degraded following parasite death: an analysis by microscopy and real-time PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Diagnostic accuracy of a new Leishmania PCR for clinical visceral leishmaniasis in Nepal and its role in diagnosis of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Post kala-azar dermal leishmaniasis: an unresolved mystery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Recent advances in post-kala-azar dermal leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Fibroblasts as host cells in latent leishmaniosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

The limits on trypanosomatid morphological diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Transcriptomics throughout the life cycle of Leishmania infantum: high down-regulation rate in the amastigote stage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Luciferase-expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Quantitative proteomic profiling of the promastigotes and the intracellular amastigotes of Leishmania donovani isolates identifies novel proteins having a role in Leishmania differentiation and intracellular survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Translational control through eIF2alpha phosphorylation during the Leishmania differentiation process

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Increased metacyclogenesis of antimony-resistant Leishmania donovani clinical lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Linking in vitro and in vivo survival of clinical Leishmania donovani strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Skewing of cytokine profiles towards T helper cell type 2 response in visceral leishmaniasis patients unresponsive to sodium antimony gluconate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Leishmania spp.: proficiency of drug-resistant parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

BALB/c mice infected with antimony treatment refractory isolate of Leishmania braziliensis present severe lesions due to IL-4 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Resistance of Leishmania (Viannia) braziliensis to nitric oxide: correlation with antimony therapy and TNF-alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in Tegumentary Leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Immunopathogenesis of infection with the visceralizing Leishmania species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Optimal dosing of miltefosine in children and adults with visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Hyperlipidemia offers protection against Leishmania donovani infection: role of membrane cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Liposomal cholesterol delivery activates the macrophage innate immune arm to facilitate intracellular Leishmania donovani killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614

Expression of IFN-gamma, TNF-alpha, IL-10 and TGF-beta in lymph nodes associates with parasite load and clinical form of disease in dogs naturally infected with Leishmania (Leishmania) chagasi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.916614